Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
Presentation Date: September 14, 2026
Time: 4:00 PM Eastern Time (Holmes 1)
Webcast Link: Available Here
A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay of the webcast will be archived and available following the event for 90 days.
Dr. Yu will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. For more information, visit kairospharma.com.
CORE IR
investors@kairospharma.com
https://investors.kairospharma.com/overview/default.aspx
View source version on businesswire.com: https://www.businesswire.com/news/home/20260909429715/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The 10 Best Companies to Invest in Now
10 Top-Performing US Dividend Stocks
United States